Skip to main content
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals — Investor Relations & Filings

Ticker · 2561 ISIN · KYG9363A1003 LEI · 254900OJ8HIP6GRV1044 HKEX Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2026-05-26 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2561

About VISEN Pharmaceuticals

http://www.visenpharma.com

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on the development and commercialization of paradigm-shifting therapies for endocrine diseases. The company is committed to addressing unmet medical needs within the Greater China market by providing innovative treatments and compassionate patient care. VISEN's core strategy involves leveraging advanced drug delivery platforms, which utilize prodrugs connected to carrier molecules via a linker structure. This technology enables the controlled, slow release of the unmodified prototype drug, ensuring sustained therapeutic action while the linker and carrier are safely excreted. VISEN serves as a key strategic partner for global biopharma companies seeking to commercialize high-quality endocrine assets in the region.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares, treasury shares, and a share repurchase report (Section II) with actual transaction details (dates, number of shares repurchased, prices). It is not an earnings release or broader financial report, but a statutory disclosure of the company’s buyback of its own shares. This aligns with the “Transaction in Own Shares (POS)” category.
2026-05-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) reporting changes in issued shares, treasury shares, on-market share repurchases, and related confirmations. It details the company’s repurchase of its own shares and treasury share transactions. Under the classification definitions, this falls squarely under “Transaction in Own Shares” (code POS), which covers share buybacks or sales of treasury shares by the issuer.
2026-05-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 87% confidence The document is Hong Kong Exchange Form FF305 “Next Day Disclosure Return” disclosing changes in issued shares and treasury shares, including detailed repurchase (buyback) transactions, prices, and board confirmations. This is a statutory filing for on-market share repurchases and treasury share transactions, matching our category for “Transaction in Own Shares.”
2026-05-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and details repurchase transactions, share counts, prices, and confirmations of compliance with listing rules. The content is regulatory in nature, reporting share repurchase activity and changes in capital structure, but it is not a full financial report, earnings release, or management discussion. It is a formal disclosure of share transactions and capital changes. Therefore, the document fits best under the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is not a brief announcement but a full disclosure report on share transactions.
2026-05-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a regulatory “Next Day Disclosure Return” (Form FF305) required under the Hong Kong Main Board/GEM listing rules to report share repurchases and changes in treasury shares. It provides detailed transaction data for the company’s own share buyback, including dates, quantities, prices, and confirmations of compliance. This clearly matches the definition of a “Transaction in Own Shares” report (share repurchase/issuance).
2026-05-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in share capital, issued shares, treasury shares, and public float sufficiency confirmation for the month ended April 30, 2026. It includes confirmations pursuant to listing rules and compliance statements by an executive director. The content focuses on share capital and share movements rather than financial performance, earnings, or management commentary. It is a regulatory compliance filing related to share capital movements and public float, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-06 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.